Background: Highly active antiretroviral therapy (HAART) has largely reduced the occurrence of AIDS-related diseases and death in HIV-infected patients. However, HAART produces serious side effects mainly attributed to mitochondrial toxicity. Methods: To elucidate the molecular basis of HAARTrelated dysfunctions, we analysed the mitochondrial proteome of peripheral blood mononuclear cells from HIV-infected patients using two-dimensional gel electrophoresis and MALDI-TOF/TOF mass spectrometry. Proteomic analysis was performed on HIV patients who were either treatment-naive or under HAART therapy including zidovudine or stavudine as nucleoside reverse transcriptase inhibitors (NRTIs). Results: As compared to healthy donors, HAART-treated HIV-infected patients exhibited decreased levels of mitochondrial enzymes associated with energy production as well as mitochondrial chaperones. Moreover, significant alterations in the mitochondria-cytoskeleton network were observed. Notably, most of these changes were already detectable in untreated HIV carriers and persisted or worsened after HAART, indicating that relevant mitochondrial alterations were initially caused by HIV infection. Finally, in vitro experiments aimed at validating the proteomic results showed that down-regulation of the mitochondrial chaperone prohibitin is a causative event in NRTI-induced mitochondrial damage.
Conclusions: Our results indicate a major role of HIV infection in the mitochondrial toxicity of HAART-treated patients and identify novel candidate markers for assessing the risk of HIV-and HAART-related pathologies.
The important progress achieved with the use of highly active antiretroviral therapy (HAART) for the treatment of HIV infection [1, 2] has been tempered by a number of side effects that account for most of the treatment interruptions [3] . Neuropathy, myopathy, hepatic steatosis, lactic acidosis, bone marrow suppression and lipodystrophy have been reported to be caused or accelerated by HAART [4] . In particular, lipodystrophy has a high incidence (30-50%) in HIV-infected individuals on prolonged HAART [5] . This disease is characterized by fat redistribution with peripheral fat loss, often concomitant with central fat accumulation [6] . Moreover, lipodystrophy is generally associated with impaired glucose and lipid metabolism, and other risk factors for cardiovascular diseases [7] .
Mitochondrial damage is considered the main cause of long-term toxicity of HAART [8, 9] . Indeed, HAARTinduced pathologies bear a notable resemblance to
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Proteomic analysis identifies prohibitin downregulation as a crucial event in the mitochondrial damage observed in HIV-infected patients Introduction genetically-based mitochondrial diseases [5, 10] . The mitochondrial pathogenesis has been mainly ascribed to the nucleoside reverse transcriptase inhibitor (NRTI) backbone of HAART [11] . In particular, both in vitro and epidemiological studies have indicated that thymidine analogues are responsible for the mitochondrial toxicity [12] . This is also supported by the reduced mitochondrial damage observed with new HAART regimens that include thymidine-sparing NRTI backbones (that is, tenofovir or abacavir) [13, 14] . Based on in vitro biochemical evidence, NRTIs have been proposed to directly inhibit DNA polymerase-γ, the mitochondrial enzyme responsible for mitochondrial DNA (mtDNA) replication [15] . This finding has been substantiated by initial observations of an in vivo decrease of mtDNA in different organs, associated with aberrant mitochondrial morphology and changes in respiratory chain enzymes [16, 17] . By contrast, recent reports have shown that HAART-associated pathologies could also occur without a significant reduction in mtDNA levels [18] [19] [20] [21] . Besides DNA polymerase-γ inhibition, the suggested mechanisms of HAART toxicity include the inhibition of endogenous nucleotide kinases, the impairment of oxidative phosphorylation, the generation of reactive oxygen species (ROS), the changes in expression of uncoupling proteins and the mutation in mitochondrial and nuclear DNA [4] . Moreover, a direct contribution of HIV infection to mitochondrial damage has been proposed in previous studies both in vitro and in vivo [22] [23] [24] , the latter mainly on the basis of mtDNA content analysis [16, 25] .
In the actual scenarios of long-term use of HAART, it is crucial to fully understand the toxic mechanisms of the drugs. In this paper we report a systematic proteomic study aimed at elucidating the mitochondrial alterations in peripheral blood mononuclear cells (PBMCs) of HIV-infected patients. Our findings show that extensive mitochondrial damage is caused by HIV infection before HAART. Moreover, using an in vitro model, we identified the down-regulation of prohibitin as a key factor in establishing HAART-dependent mitochondrial toxicity.
Methods

Patients
Patients were recruited at the outpatient clinic of the Spallanzani Institute (Rome, Italy) from July 2004 to January 2005, according to the following criteria: caucasian race, chronic HIV infection, absence of a previous diagnosis of AIDS or acute illnesses, CD4 + T-cell count >350 cells/mm 3 , low level of HIV RNA, and on the same HAART regimen for ≥1 year including lamivudine (3TC; 2′,3′-dideoxy-3′-thiacytidine) plus a thymidine analogue, either zidovudine (AZT; azidothymidine) or stavudine (d4T; 2′-3′-didehydro-2′-3′-dideoxythymidine), with a regular drug supply as a rough indicator of adherence. Patients taking AZT were selected among those never exposed to d4T. Healthy patients and chronic HIV-infected patients naive to HAART were recruited as controls. The diagnosis of lipodystrophy was done by considering the presence of facial and peripheral fat loss, abdominal obesity, buffalo hump and gynaecomastia. For each patient, data regarding demographic characteristics, HIV infection and antiretroviral history, presence of coinfection, presence of illnesses possibly related with mitochondrial toxicity (peripheral neurophathy, hepatopathy, pancreatitis and rhabdomyolysis), and immunological, virological and biochemical parameters were collected. The study was approved by the National Institute of Infectious Disease ethics committee (Protocol Ethics Commmittee number 326-09/06/2004), and patients provided written informed consent before enrolment.
Two-dimensional gel electrophoresis
Mitochondrial fractions were suspended in urea buffer (7 M urea, 2 M thiourea, 2% chaps, 1% sulfobetaine SB3-10, 1% amidosulfobetaine ASB14 and 50 mM DTT; all reagents from Sigma-Aldrich, St. Louis, MO, USA). Proteins (200 µg) were subjected to isoelectric focusing using 18 cm immobilized linear pH gradient strips (IPG; pH 4.0-7.0; GE Healthcare, Little Chalfont, Buckinghamshire, UK) on an IPGphor II electrophoresis unit (GE Healthcare). Protein samples diluted in 350 µl of rehydratation buffer (6 M urea, 2 M thiourea, 4% chaps, 65 mM DTT, 0.5% IPG buffer pH4.0-7.0 [GE Healthcare] and 1% bromophenol blue) were loaded on IPG strips by active in-gel rehydratation applying low voltage (30 V) for 9 h. Isoelectric focusing was conducted at 20°C for 45,000 V/h with a limiting current of 50 µA/strip. Before the second dimension, proteins were subjected to reduction and alkylation by incubating IPG strips in equilibration buffer (6 M urea, 2% SDS, 30% glycerol and 50 mM TrisHCl, pH 8.8) containing 1% DTT for 10 min, followed by incubation in equilibration buffer containing 4% iodoacetamide for 10 min. Strips were then transferred to 1 mm thick 10% polyacrylamide gels (20×20 cm), and gels were run at 50 mA for 6 h. Gels were stained with Sypro Ruby (BioRad, Hercules, CA, USA) according to the manufacturer's instructions and visualized using a Typhoon 9200 scanner (GE Healthcare). Each sample was run in triplicate. The Investigator HT analyser (Genomic Solutions, Inc., Ann Arbor, MI, USA) was used for matching and analysing the visualized protein spots within different gels. Spot volumes were corrected for background by using the 'average on boundary' mode of background subtraction and total spot volume normalization was applied to allow comparison of measurements between gels. The normalized intensity values of individual protein spots were then used to determine differential protein expression between groups by statistical analyses. For each protein spot, three separate fold changes were then calculated (HIV-positive treatment-naive versus healthy donor; AZT plus 3TC versus healthy donor; d4T plus 3TC versus healthy donor). The level of significance was considered when P<0.05 as well as when a twofold difference, either increase or decrease, between the HIV-infected patients and healthy donor groups was detected.
In-gel tryptic digestion and MALDI-TOF/TOF analysis Spots were excised from the gels with an automatic spot picker (Investigator ProPic; Genomic Solutions Inc.) and subjected to in-gel tryptic digestion. Briefly, proteincontaining gel pieces were destained by adding 0.1 M ammonium bicarbonate (50 µl, 5 min at room temperature) followed by an equal volume of 100% acetonitrile (ACN). The washing step was repeated twice. Gel plugs were then shrunk by addition of 100% ACN. The dried gel pieces were reswollen with 4.5 ng/ml trypsin in 50 mM ammonium bicarbonate and digested overnight at 37°C. Peptides were concentrated with ZipTip µC18 pipette tips. Coelution was performed directly onto a MALDI target with 1 µl of a-cyano-4-hydroxycinnamic acid matrix (5 mg/ml in 50% ACN 0.1% TFA).
MALDI-mass spectrometry (MS) and MALDI-MS/ MS were performed on an Applied Biosystems 4700 Proteomics Analyzer with TOF/TOF ion optics (Applied Biosystems, Foster City, CA, USA). The spectra were acquired in the positive reflector mode in an 800-4,000 mass range. Peak labelling was automatically done by 4000 Series Explorer Software version 3.0 (Applied Biosystems). Spectra were calibrated either externally using five peaks of standard (ABI4700 Calibration Mixture; Applied Biosystems) or internally using porcine trypsin autolysis peptide peaks (m/z=842.510, 1,045.564, 2,211.105, 2,239.136 and 2,807.300). In addition to peptide mass finger spectra, the five most abundant precursor ions masses having a signal-to-noise ratio >50 were chosen for MS/MS fragmentation. The interpretation of both the MS and MS/MS data was carried out with the GPS Explorer software (version 3.6; Applied Biosystems). Peaks were extracted from raw spectra by the GPS Explorer software. A combined MS peptide fingerprint and MS/MS peptide sequencing search was performed against the NCBI non-redundant database without taxon restriction using the MASCOT search algorithm. These searches specified trypsin as the digestion enzyme, carbamidomethylation of cysteine as fixed modification, partial oxidation of methionine and phosphorylation of serine, threonine, and tyrosine as variable modifications, and allowed for one missed trypsin cleavage. The monoisotopic precursor ion tolerance was set to 50-70 ppm and the MS/MS ion tolerance to 0.3 Da. MS/MS peptide spectra with a minimum ion score confidence interval ≥95% were accepted; this was equivalent to a median ion score cutoff of approximately 35 in the data set. Protein identifications were accepted with a statistically significant MASCOT protein search score ≥76 that corresponded to an error probability of P<0.05 in our data set.
Immunofluorescence analyses
PBMCs were fixed with 4% paraformaldehyde in phosphate-buffered saline and permeabilized with ethanol. Samples were incubated with primary antibodies
and anti-ALDH2 [K-15]; Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-mitochondria (Chemicon, Millipore, Billerica, MA, USA), anti-F1-ATPase a-subunit (Molecular Probes, Invitrogen, Carlsbad, CA, USA), followed by AlexaFluor594 or AlexaFluor488-conjugated secondary antibodies (Molecular Probes). Samples were then plated on coverslips by centrifugation with Cytospin (Shandon Southern Instruments, Inc., Sewickley, PA, USA) and analysed using a Nikon Microphot fluorescence microscope (Nikon, Shinjuku, Tokyo, Japan) or a confocal microscope (Leica TCS-SP2; Leica Microsystems, Mannheim, Germany). 
Transmission electron microscopy
PBMCs were fixed in 2.5% cacodylate-buffered glutaraldehyde and post-fixed in 1% cacodylate buffered OsO 4 . Fixed specimens were dehydrated through a graded series of ethanol solutions and embedded in Agar100 (Agar-Aids, Stansted, Essex, UK). Serial ultrathin sections were collected on 200-mesh grids and counterstained with uranyl acetate and lead citrate. Sections were observed with a Phillips EM 208 electron microscope (Phillips, Eindhoven, the Netherlands). Morphometric analyses were performed by evaluating 20 fields of each sample (≥100 cells) at the same magnification (10,000×). The percentage of cells showing mitochondrial coalescence or mitochondria with budding structures was assessed.
Supplementary details of methods, including a description of cell culture and chemicals, complementary DNA cloning, retrovirus generation and infection, RNA interference, western blot, realtime PCR, ROS measurement and statistical analyses can be found in Additional file 1.
Results
To obtain a comprehensive view of the mitochondrial alterations occurring in HIV-infected patients, we analysed the changes in the mitochondrial protein profile using a proteomic approach.
Patient characteristics
HAART-treated HIV-infected patients were grouped according to the following two criteria: the exposure to thymidine analogues (AZT or d4T) as HAART backbone; and the presence or absence of lipodystrophy symptoms. HIV-infected patients naive to HAART and healthy donors were also included in the study. The general and clinical characteristics of the patients are summarized in Supplementary Table 1 (see Additional  file 2). Treatment-naive and HAART-treated groups showed no difference according to sex, age, HIV risk factors, CD4 + T-cell count, body mass index, the presence of peripheral neuropathy, HCV or HBV coinfections, hyperglycaemia, hypertriglyceridaemia, combined metabolic disorders, hypertransaminasaemia and hyperamylasaemia, except for a higher percentage of females among d4T-treated patients without lipodystrophy. No symptoms of pancreatitis, hepatopathy or myopathy were reported. Exposure time to the same thymidine analogue and to protease inhibitors was similar among different HAART-treated groups. Some expected differences were observed: treatment-naive patients had lower levels of leukocytes (P=0.02), no case of hypercholesterolaemia (P=0.005) and a higher level of HIV RNA (P<0.001). Hyperlactataemia was significantly more frequent in lipodystrophic than in both non-lipodystrophic and treatment-naive groups (P=0.05). Finally, non-lipodystrophic d4T-treated patients had more exposure to didanosine than the other treated groups (17 months versus no exposure for non-lipodystrophic AZT, 6 months for lipodystrophic AZT and 7 months for lipodystrophic d4T group; P=0.02).
Proteomic analysis of mitochondrial alterations in HIV-infected patients
Because of the limited amount of mitochondrial proteins obtained from single donors, the proteomic analyses were performed on pooled PBMCs collected from eight patients. Protein extracts from isolated mitochondria were analysed by two-dimensional gel electrophoresis (2DE; see Supplementary Figure 1 in Additional file 3) and protein spot profiles were compared. Spots differentially expressed in comparison with healthy controls are shown in Figure 1 . Notably, most of the observed changes were common to all HIV-infected patients independently of HAART, indicating that relevant mitochondrial alterations are initially caused by HIV infection. Conversely, no differences were observed by comparing mitochondrial proteomes of patients with or without lipodystrophy symptoms within the same therapeutic regime (FC et al., data not shown).
Proteins with decreased levels in mitochondria of HIV-infected patients MALDI-TOF/TOF MS analysis was carried out to identify the mitochondrial proteome changes of HIVinfected patients. As described in Table 1 and Supplementary Table 2 (see Additional file 4) spots with a decreased intensity in all three groups of HIV patients correspond to proteins involved in major mitochondrial metabolic pathways including the respiratory chain, the Krebs cycle and the fatty acid β-oxidation. Notably, HAART-treated patients showed specific alterations in the respiratory chain (cytochrome c oxidase subunit Va) and nucleotide metabolism (nucleoside diphosphate kinase). Conversely, mitochondria from naive patients exhibited lower levels of PRDX4, a protein involved in redox balance, as well as succinyl-CoA:3-ketoacid-CoA transferase, an enzyme of the ketolysis pathway, and ETHE1, a protein of unknown function whose mutation causes the ethylmalonic encephalopathy syndrome.
In order to rule out the possibility that our proteomic results were affected by the experimental settings, that is, the analysis of a pool of mitochondrial proteins from a limited number of patients and/or the gel-to-gel variability of the 2DE, a series of validation experiments was carried out. As reported in Figure 2A , the decrease in the mitochondrial levels of a selection of proteins identified in the proteomic screening was confirmed by western blot analysis on individual patients, with the exception of the F1 ATPase a-subunit. However, it is to be noted that the F1 ATPase spots identified in the 2DE map correspond to low molecular weight isoforms, possibly derived from protein cleavage, that might not be recognized by the monoclonal antibody we used. Western blot analysis performed on total protein extracts showed that only prohibitin and cytochrome c oxidase subunit Va levels were significantly decreased ( Figure  2B and Supplementary Figure 2 [see Additional file 5]), suggesting that the observed alterations could be due either to a reduction in the total protein amount or to a different subcellular localization.
Proteins with increased levels in mitochondria of HIV-infected patients
Among the proteins whose levels were increased in PBMCs of HIV-infected patients, the majority were catalogued as non-mitochondrial proteins (Table 1  and Supplementary Table 2 [see Additional file 4]).
The most represented group of proteins was related to cytoskeletal dynamics, suggesting that a rearrangement of the mitochondria-cytoskeleton interaction occurs in PBMCs of HIV-infected patients. Some cytoskeletal proteins exclusively accumulated in the mitochondria of HAART-treated patients (such as l-plastin and Unc112-2), indicating a specific contribution of HAART to cytoskeletal alterations. An increase of proteins regulating the vesicular trafficking, such as Rab proteins, were also observed implying that the interaction between mitochondria and other organelles could be altered. Concerning the other increased proteins, many were related to the ubiquitin system, suggesting an enhanced proteasome-mediated degradation in mitochondria from HIV-infected patients, or were proteins involved in different signal transduction pathways, such as G proteins, protein kinase A and protein phosphate 2A.
The increase of TCP1, G-ai2, annexin VI and Rab1 in the mitochondrial fraction was confirmed by western blot or immunofluorescence analysis of PBMCs from individual patients ( To correlate the observed alterations with changes in mitochondrial ultrastructure, we performed transmission electron microscopy. In comparison to healthy donors, PBMCs from HIV treatment-naive patients showed a high number of mitochondria with associated vesicle structures, suggestive of an abnormal fission process ( Figure 2E ). By contrast, HAART-treated patients displayed a fivefold increase in mitochondria with adjacent associations, reminiscent of mitochondrial coalescence ( Figure 2E ). These observations could indicate a consistent rearrangement of the network between mitochondria, cytoskeleton and vesicle trafficking in HIV-infected patients.
Role of prohibitin dysregulation in the mitochondrial damage induced by NRTI
To elucidate the role of the proteins identified in proteomic analysis in promoting the mitochondrial toxicity observed in HIV-infected patients, we undertook a series of in vitro experiments. First, we tested the effect of AZT or d4T, in combination with 3TC, on the mitochondrial levels of these proteins in the human CEM T-cell line. As
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Citric acid cycle/pyruvate dehydrogenase Values refer to the numbers of proteins whose expression is modulated in each group of HIV patients. Note that proteins that were the same could be included in more than one group of patients if diverse spots corresponding to the same protein were found differentially modulated. a Proteins whose expression is modulated both in HIV patients who were treatment-naive and in HIV patients treated with highly active antiretroviral therapy (HAART) including zidovudine (AZT) or stavudine (d4T). b Proteins whose expression is modulated only in HIV patients treated with HAART including AZT or d4T. were treated with AZT plus 3TC or d4T plus 3TC (7, 14, 7 and 3 days, respectively) and prohibitin levels measured by western blot. HSP, heat shock protein; RL, relative levels.
shown in Figure 3A , an alteration in their mitochondrial levels was already detectable after 1 week of treatment, thus demonstrating that these proteins are early targets of NRTI. Similar to what was observed in patients, a decrease in prohibitin was also detected when whole cell extracts were analysed ( Figure 3B ), paralleled by a reduction in its RNA levels ( Figure 3E ). By contrast, other proteins, such as ALDH2, showed a decreased mitochondrial localization without a significant reduction in their expression levels ( Figure 3C and 3D) .
These results prompted us to further investigate the role of prohibitin in NRTI-induced mitochondrial toxicity. First, we verified that the effect of NRTI on prohibitin levels was not restricted to CEM cells. As shown in Figure 3F , NRTI decreased prohibitin levels in another T-cell line, in PBMCs and in fibroblasts as well as in hepatocytes. We next determined the effect of the modulation of prohibitin levels on NRTI-induced mitochondrial dysfunction. Mitochondrial damage was monitored by measuring ROS production after NRTI Figure 4A and 4B). Prohibitin expression was down-regulated by RNA interference in fibroblast cells and ROS production was measured in control and NRTI-treated cells. As reported in Figure 4C , the reduction of prohibitin expression sufficed to induce an increase in ROS production that was further enhanced upon treatment with different combinations of NRTI. Finally, we tested whether the maintenance of prohibitin expression following NRTI treatment would attenuate mitochondrial damage. Prohibitin was ectopically expressed by retroviral infection and ROS were measured after NRTI treatment. prohibitin overexpression led to a significant reduction of ROS production, indicating its protective role in NRTI-induced mitochondrial damage ( Figure 4D ).
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Discussion
In this study, we reported a proteomic approach aimed at elucidating the molecular basis of the mitochondrial dysfunction in HIV-infected patients. Three main outcomes arise from our analysis: substantial mitochondrial alterations are present in HIV-infected patients before HAART; most of the changes observed in treatmentnaive patients persist following HAART administration; and a restricted set of alterations is specifically induced by HAART. Further studies are required to determine whether the modified mitochondrial proteome profile observed in HAART-naive patients is directly caused by the expression of HIV proteins in infected cells or is caused by a systemic effect of HIV infection, for example, the increased levels of proinflammatory cytokines, which have mitochondria as targets [26] . Interestingly, proinflammatory cytokines, such as tumour necrosis factor-a, have been proposed to play a role both in HIV-and HAART-induced mitochondrial damage [26] , thus possibly explaining why HIV treatment-naive and HAART-treated patients share most of the observed mitochondrial alterations. It is worth noting that we did not detect any difference when the mitochondrial proteomes of HAART-treated patients with or without lipodystrophy were compared, suggesting that the onset of lipodystrophy is not accompanied by a worsening of the mitochondrial damage in PBMCs. However, it would be interesting to test whether the levels of the proteins identified in our screening could have a prognostic value when analysed in adipocytes.
Two main features characterized the mitochondrial alterations that we have observed in HIV-infected patients. First, we detected a significant decrease in proteins playing key roles in the major mitochondrial functions. This effect could not directly be explained by the reported depletion of mtDNA by HAART [16, 17] , as none of the modified proteins are encoded by the mitochondrial genome. Among these proteins, prohibitin deserves particular attention because its decrease could provide an explanation for the general mitochondrial alterations observed in HIV patients. Indeed, it is well known that prohibitin controls the activity or steady-state levels of many nuclear-encoded mitochondrial proteins ensuring mitochondrial genome integrity, gene expression and protein assembly [27] [28] [29] . Prohibitins are evolutionarily conserved mitochondrial proteins involved in the regulation of many cellular processes, such as apoptosis, cell cycle regulation, ageing, innate immunity and protection against oxidative stress [29] [30] [31] [32] [33] . Importantly, prohibitin has been recently described as being downregulated in Crohn's disease and has been proposed as a cellular defence against oxidant injury [32] . Here we showed that mitochondrial levels of prohibitin are down-regulated in HIV-infected patients. According to the proposed function of prohibitin, we found that HIV patients display a selective mitochondrial reduction of a set of nuclear-encoded proteins, suggesting a defect in the mitochondrial translocation/stability system. These alterations were confirmed by in vitro experiments showing that NRTI treatment leads to a rapid decrease of prohibitin paralleled by a reduced mitochondrial localization of ALDH2 protein (Figure 3C) . Moreover, prohibitin overexpression protects cells from oxidative stress induced by NRTI, whereas its knockdown provokes an increased production of ROS. Interestingly, prohibitin down-regulation could play a role in the mtDNA decrease observed in HIVinfected patients. Indeed, recent findings have demonstrated that prohibitin is essential for the maintenance of the mitochondrial nucleoid organization and mtDNA copy number [34] . It is also important to note that a deficiency in heat shock protein 60, another mitochondrial chaperone protein whose levels decreased in HIV-infected patients, is linked to an atypical mitochondria syndrome involving multisystem failure [35, 36] .
Notably, previous proteomic studies on ex vivo HIVinfected primary CD4 + T-cells reported a decrease of mitochondrial translocase proteins TOMM40 and TOMM70. Taken together with our data, these results suggest that HIV interferes with the mitochondrial import/stability system by targeting different steps [37] . By contrast, proteomic analyses performed on HIVinfected tumour cell lines revealed an increase rather than a decrease in the levels of several mitochondrial proteins. This discrepancy could be possibly a result of the transformed state of these cells and their low susceptibility to HIV-induced cell death [38] .
The second peculiar feature observed in the mitochondrial proteome of HIV patients was an increase of several proteins involved in regulating cytoskeletal dynamics and vesicle trafficking. Although the effect of HIV infection on cytoskeletal function has been largely documented [37, 39] , our study uncovers specific alterations at the level of the cytoskeleton-mitochondria network. Most of the enriched proteins are involved in the assembly of F-actin or in the interaction between membrane structures and the cytoskeletal network. It is well known that the interactions of mitochondria with the cytoskeleton are crucial for normal mitochondrial function and their localization at the sites of action [40] . These interactions influence mitochondrial respiratory activity, fusion, fission and inheritance, localization of mitochondria at sites of high energy demand, metabolite and ROS biogenesis, calcium homeostasis and/ or the release of mitochondrial apoptotic factors [41] . Moreover, dysfunctional mitochondria move along the cytoskeletal network in order to undergo repair by fusion with healthy mitochondria or to be degraded by mitophagy [40, 42] . The integrity of the actin cytoskeleton is one of the earliest targets of the toxicity of ROS in many cell types. Acute oxidative insults produce a severe disruption of the microfilament cytoskeleton characterized by the fragmentation and patching of F-actin [43] . By contrast, more 'physiological' increases in ROS, as they occur, for instance, in the context of inflammation, lead to the appearance of dense stress fibres associated with the recruitment of different proteins to focal adhesions, events considered important for intercellular contacts and migration [44] . Our data give indications for a profound reorganization of mitochondria-cytoskeletal interactions in HIV patients possibly because of increased ROS levels. In line with these results, we observed mitochondrial morphology alterations in PBMC from HIV-infected patients characterized by vesicle-like structures associated with mitochondria and aberrantly fused mitochondria. Mitochondria remodelling is under the control of cytoskeletal elements and associated with a scrambling process occurring between vesicular structures (for example, Golgi and endocytic compartments) and mitochondria [45] . Interestingly, Rab1 or annexin VI, two of the enriched proteins in the mitochondria of HIV-infected patients, have been described to be involved in this complex framework regulating organelle scrambling [46, 47] . Mitochondria remodelling is dependent on glycosphingolipid-enriched microdomains, such as the lipid rafts. These domains have been found to be involved in HIV infection [48] and their function altered during HAART [49] . Based on these observations, it would be interesting to test whether alterations in the lipid rafts could contribute to the mitochondrial changes here described.
In conclusion, our data highlighted a major alteration of the mitochondrial proteome in HIV patients before HAART pointing out a potential advantage of a pretherapeutic mitochondrial functionality analysis in order to assess the risk of developing HAARTdependent mitochondrial toxicities. Recent data suggest that uncontrolled HIV replication, such as that observed during antiretroviral treatment interruption, may have detrimental effects on non-AIDS disease progression even at high CD4 + T-cell count, because of the negative effects of immune activation [50] . It would be now relevant to assess whether HIV-induced mitochondrial damage observed before HAART exposure is a biological determinant of this clinical outcome.
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